Archive

Posts tagged under: immunotherapy

Get your FREE Immuno-Oncology Therapy Analysis by ta-Scan

Today brings the start of the Immuno-Oncology Summit 2017 in Boston, supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

MDCPartners and its ta-Scan team contribute to this purpose by teaching how clinical planners can leverage our clinical businesses intelligence software and our data merging services to get to their answers faster. The ta-Scan team created a useful analysis on oncolytic virus therapies in clinical trials. We thought today would be a good occasion to share this report with you.

>>> Click here to download the analysis <<<

Connect with MDCPartners at the Immuno-Oncology Summit 2017

Connect with MDCPartners at Immuno-Oncology Summit 2017 from August 28 to September 1, 2017 in Boston, MA. Visit MDCPartners at booth #32 to discover next generation targeted immunotherapies and find new ways to navigate clinical data and overlap internal data with MDCPartners’ public data cloud.

Join us in Boston

Would you like to know how our clinical business intelligence software ta-Scan or our other data solutions can help with your company’s data challenges? Then feel free to pop by booth #32 or make an appointment with MDCPartners’ Director of Business Development, North America Matt Tumasz and/or Strategic Analyst, Oncology, Dr. Jonathan Crowther. They will gladly show you our state of the art tools.

Register Today

Secure your place now if you want to connect with the ta-Scan team in Boston. MDCPartners has arranged for an exclusive discount on CHI’s Immuno-Oncology Summit. Use promo code MDC when registering to receive your $200 registration discount. This discount applies to conference programs only and cannot be used on short courses, combined with other offers, or transferred.

How to register:
Online: https://chidb.com/reg/imx/reg.asp
By Phone: +1 781-972-5472

Immuno-Oncology Summit 2017 Program

Now in its fifth year, the Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

This year’s IO Summit has been designed to give attendees a complete picture of the field and its advances with 12 conference tracks, 1 in-depth training seminar, and 4 instructional short courses. Topics include immunotherapy discovery, development, biomarkers, and translational oncology as well as emerging topic areas such as cancer vaccines, oncolytic viruses, and advances in synthetic biology techniques. Overall, this event provides a focused look at how researchers are applying new science and technology in the development of effective and safe immunotherapies.

Download the digital brochure for full details.

We look forward to seeing you in Boston!

Meet the ta-Scan Team at Immunotherapy Leaders Europe

Immuno-oncology in Berlin

Enjoying the summer, we are also excited about what comes after: in September, the ta-Scan team will be present at Immunotherapy Leaders Europe, the annual meeting for Immuno-Oncologists in Berlin.

Biomarkers for patient selection

Learn how to use our clinical business intelligence portal ta-Scan to boost success rates in immuno-oncology clinical trials through biomarker-driven patient selection from Strategic Analyst Oncology Dr Jonathan Crowther‘s presentation on:

Biomarker evolution and utility for patient selection in clinical research

Wednesday, September 21,  2:45 – 3:05 PM
Stream 3: Boosting success rates in immuno-oncology clinical trials
through biomarker-driven patient selection

  • Using the clinical business intelligence platform ta-Scan to track the evolution of immunotherapy biomarkers and improve patient selection resulting in successful clinical research.
  • Analysis of the immuno-oncology biomarker landscape: What are the trending biomarkers and how do they compare across clinical research?
  • Improving on study design, the who and where in clinical research.
    –  Estimation of patient cohorts?
    –  Key opinion leaders in the field?
    –  What benchmarks have been previously established?
  • Geographical site selection
    –  Where are trials primarily taking place?
    –  What countries and locations are suitable for my trial?

Dr Jonathan Crowther


Jonathan Crowther Immunotherapy Europe ta-Scan MDCPartners

Jonathan Crowther is Strategic Analyst Oncology at MDCPartners where he is working on growing oncology-based projects on the ta-Scan platform. Jonathan holds a PhD from the VIB/University of Leuven (Belgium) where he studied the role of large scale deletions in cancer and explored their potential as novel biomarkers of drug response. Jonathan provided bioinformatic analysis and big data solutions to ongoing areas of research, working on large cancer patient data sets such as The Cancer Genome Atlas (TCGA). In this capacity Jonathan significantly contributed to a number of ongoing projects and has published on these topics.

Meeting up

You can also meet us personally at booth #27 to see a live demonstration of our ta-Scan software. Just drop by or make an appointment with David Cocker or Jonathan Crowther.

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page